Back to top
more

Deciphera Pharmaceuticals (DCPH)

(Delayed Data from NSDQ)

$25.46 USD

25.46
1,152,881

+0.01 (0.04%)

Updated May 17, 2024 04:00 PM ET

After-Market: $25.47 +0.01 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Is the Options Market Predicting a Spike in Deciphera (DCPH) Stock?

by Zacks Equity Research

Investors need to pay close attention to Deciphera (DCPH) stock based on the movements in the options market lately.

Deciphera Pharmaceuticals, Inc. (DCPH) Down 0.8% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Deciphera Pharmaceuticals, Inc. (DCPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Deciphera (DCPH) Q2 Loss Wider Than Expected, Revenues Beat

by Zacks Equity Research

Deciphera (DCPH) posts wider-than-expected loss in the second quarter due to rising R&D costs. Sales beat estimates on the encouraging uptake of Qinlock.

Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of -5.22% and 5.95%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Deciphera Pharmaceuticals, Inc. (DCPH) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

by Zacks Equity Research

Deciphera Pharmaceuticals, Inc. (DCPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Deciphera (DCPH) Begins Dosing in Study on Cancer Candidate

by Zacks Equity Research

Deciphera (DCPH) doses the first patient in a phase I study evaluating its ULK kinase inhibitor, DCC-3116, for treating advanced/metastatic tumors driven by mutations in RAS/RAF genes.

Why Is Deciphera Pharmaceuticals, Inc. (DCPH) Down 10.8% Since Last Earnings Report?

by Zacks Equity Research

Deciphera Pharmaceuticals, Inc. (DCPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Deciphera (DCPH) Q1 Loss Narrower Than Expected, Revenues Beat

by Zacks Equity Research

Deciphera (DCPH) posts a narrower loss in the first quarter while sales beat on the encouraging uptake of Qinlock.

Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of 1.85% and 8.89%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Deciphera Pharmaceuticals, Inc. (DCPH) Surges 8.8%: Is This an Indication of Further Gains?

by Zacks Equity Research

Deciphera Pharmaceuticals, Inc. (DCPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Deciphera (DCPH) Reports Narrower-Than-Expected Q4 Loss

by Zacks Equity Research

Deciphera Pharmaceuticals (DCPH) reports narrower-than-expected loss. Nonetheless, sales marginally surpass estimates for the fourth quarter of 2020.

Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of 5.17% and 4.32%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Baudax (BXRX) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Baudax (BXRX) will provide updates on earnings and revenues when it releases results for fourth-quarter 2020.

Blueprint Medicines (BPMC) Rises 40% in Past 3 Months: Here's Why

by Zacks Equity Research

Blueprint Medicines' (BPMC) lead drug, Ayvakit, approved for PDGFRA Exon 18 mutant GIST is off to a solid start. The company's second drug, Gavreto, gets approved for two types of cancer indications.

    The Zacks Analyst Blog Highlights: BioMarin Pharmaceutical, uniQure, REGENXBIO and Deciphera Pharmaceuticals

    by Zacks Equity Research

    The Zacks Analyst Blog Highlights: BioMarin Pharmaceutical, uniQure, REGENXBIO and Deciphera Pharmaceuticals

    4 Biotechs That Could Be Potential Acquisition Targets in 2021

    by Zacks Equity Research

    We discuss a few attractive biotech companies that flaunt solid product portfolios, deep pipelines and lucrative valuations to emerge as likely acquisition targets in 2021.

    Deciphera (DCPH) Ends Qinlock Second-Line GIST Study Enrollment

    by Zacks Equity Research

    Deciphera (DCPH) completes enrollment in the phase III study evaluating Qinlock in patients with second-line gastrointestinal stromal tumor.

    Deciphera (DCPH) Reports Narrower-Than-Expected Loss in Q3

    by Zacks Equity Research

    Deciphera (DCPH) reports a narrower-than-expected loss and sales beat estimates in the third quarter of 2020.

    Blueprint Medicines Rises YTD on Robust Ayvakit Progress

    by Zacks Equity Research

    Blueprint Medicines' (BPMC) lead drug Ayvakyt/Ayvakit approved for PDGFRA Exon 18 mutant GIST is off to a solid start. The company's efforts to expand the drug's label are promising as well.

    Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q2 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of 10.45% and 249.26%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

    Deciphera (DCPH) Secures Early FDA Nod for GIST Drug Qinlock

    by Zacks Equity Research

    The FDA lends a speedy nod to Deciphera's (DCPH) Qinlock for the treatment of fourth-line gastrointestinal stromal tumors. The approval comes three months ahead of schedule.

    Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q1 Loss, Misses Revenue Estimates

    by Zacks Equity Research

    Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of -6.25% and -97.52%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

    Is a Surprise Coming for Deciphera (DCPH) This Earnings Season?

    by Zacks Equity Research

    Deciphera (DCPH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

    Is Deciphera Pharmaceuticals (DCPH) Stock a Solid Choice Right Now?

    by Zacks Equity Research

    Deciphera Pharmaceuticals (DCPH) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

      Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q4 Loss, Misses Revenue Estimates

      by Zacks Equity Research

      Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of -15.93% and -100.00%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?